What is Acrux?
Acrux is a specialty pharmaceutical company dedicated to the development and commercialization of topical and transdermal prescription medicines for global healthcare markets. The company's core focus lies in creating innovative generic and branded drug delivery systems, including sprays, gels, creams, and solutions, designed to enhance patient convenience and treatment efficacy. Acrux collaborates with international partners to bring regulated pharmaceutical products to market, leveraging its in-house expertise in formulation, development, and manufacturing of skin-applied therapies.
How much funding has Acrux raised?
Acrux has raised a total of $1.6M across 1 funding round:
Stock/Share Issuance
$1.6M
Stock/Share Issuance (2026): $1.6M, investors not publicly disclosed
What's next for Acrux?
The recent major strategic investment signals a pivotal moment for Acrux, likely enabling the company to accelerate its product development pipeline, expand its market reach, and potentially scale its manufacturing capabilities. This enterprise-level funding suggests a strategic focus on growth and market penetration, positioning Acrux to further solidify its presence in the competitive specialty pharmaceutical landscape. Future endeavors may include advancing existing drug delivery platforms and exploring new therapeutic areas for topical and transdermal applications.
See full Acrux company page
